Treatment of contralateral tumors with intratumoral administration of AdmCD40L-modified DCs.
(A) Tumor growth. C57Bl/6 mice were injected in both flanks with 5 × 105 B16 tumor cells (day 0). On day 8, the bilateral tumor-bearing mice intratumorally received 2 × 105 DCs that had been modified in vitro with AdmCD40L (▪), or AdNull (○) in the tumors in the left flank. Controls included bilateral tumor-bearing mice without any treatment (Δ). A parallel group of control mice were injected in the left Lewis lung carcinoma tumors with AdmCD40L-transduced DCs (treatment for a different tumor type than the right B16 tumors; ▪). The size of right tumors is reported as at the average tumor area (mm2) ± standard error of n = 5 per group. Asterisks indicate significant differences at 95% confidence limits between AdmCD40L-transduced DCs in syngenic tumors and all other surviving groups. (B) Survival. The survival of animals in panel A was recorded as the percentage of animals in each group (Kaplan-Meir analysis, P < .05 AdmCD40L-transduced DCs for syngenic tumors compared with all other groups).
